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o the effects of hookworm anemia. Trichuris is an important
elminth in which most cases of are asymptomatic. Heavy
nfections can result in the Trichuris dysentery syndrome
TDS). This syndrome includes chronic dysentery, rectal pro-
apse, anaemia, poor growth, and clubbing of the ﬁngers.
he severe stunting in TDS now appears likely to be a reac-
ion at least in part to a chronic inﬂammatory response and
oncomitant decreases in plasma insulin, plasma insulin-
ike growth factor-1 (IGF-1), increases in tumor necrosis
actor-(TNF-) in the lamina propria of the colonic mucosa
nd peripheral blood (which likely decreases appetite and
ntake of all nutrients) and a decrease in collagen synthe-
is. Improvements in cognitive performance have been found
fter treatment for relatively heavy infections in school
ge children. Synergistic associations between hookworm
nd other helminths has been described. In a recent study
rom Brazil, 61% of individuals harbored mixed helminth
nfections. Multivariate analysis indicated signiﬁcant pos-
tive associations for co-infection with hookworm and S.
ansoni and for co-infection with hookworm and A. lum-
ricoides. Co-infection with hookworm and Ascaris resulted
n higher egg counts for both, suggesting a synergistic rela-
ionship between these species, although, the intensity of
. mansoni or A. lumbricoides co-infection did not differ
rom that of mono-infection. Another study from from Brazil
ooking at Hookworm and Ascaris infection and the impact
f polyparasitism on cognitive performance in Brazilian
choolchildren suggested that hookworm may be associated
ith poorer concentration and information processing skills
hile A. lumbricoides infection may be associated with
oorer general intelligence. Polyparasitized children seem
o experience worse outcomes that children with only one
elminth infection. In yet another study, multivariate anal-
sis revealed that stunting was signiﬁcantly associated with
scaris infection among children and adolescents, whereas
ow body mass was signiﬁcantly associated with hookworm
nfection among adults and the elderly.
Strongyloides stercoralis can cause acute infection,
hronic infection and hyperinfection syndrome. Hyperinfec-
ion syndrome has been associated with a variety of risk
actors and predisposing conditions, including new immuno-
uppressive therapy therapies; HTLV-1 infection; cadaveric
ransplantation; immune reconstitution syndrome; hema-
ological malignancies (especially lymphoma). Co-infection
ith with HTLV-1 results in decreases in IL-5, and parasite
peciﬁc IgE responses in patients with strongyloidiasis con-
istent with a relative switch from Th1 to Th2 response
eading to an increased risk of autoinfection resulting in
yperinfection syndrome. Co-infected patients with HTLV-1
nd strongyloides may not respond as well to anti-helminth
reatment. In addition to HTLV-1, corticosteroid use remains
ne of the most frequent risk factors for hyperinfection
yndrome. Hyperinfection syndrome presents with diverse
ymptoms and signs often leading to misdiagnosis on the
linicians part. It is associated with a high mortality rate
15-87%). Therefore, increased recognition is important for
linicians caring for at-risk patients.Of the ﬁve major species of Schistosomiasis pathogenic
o humans the only one endemic in South America is Schisto-
oma mansoni. Despite the efforts in carrying out integrated
ontrol programs during the last 25 years, there are still
egions where the prevalence of S. mansoni is over 50%.
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eavily infected, susceptible individuals are at risk for
eveloping hepatosplenic disease. Pulmonary involvement
n S. mansoni is reported in acute schistosomiasis and in
hronic disease. Recent studies from Brazil suggest that pul-
onary hypertension may be more common than previously
hought in individuals with hepatosplenic disease due to S.
ansoni. Similarly, recent studies suggest that hepatopul-
onary syndrome also occurs in patients with S. mansoni
ho also have periportal ﬁbrosis and portal hypertension.
lthough CNS involvement is rare, it is well described. Trans-
erse myelitis or seizures have been described in both acute
nd chronic infection.
oi:10.1016/j.ijid.2010.02.1512
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ood-borne Toxins
. Ansdell
Kaiser Honolulu Clinic, Tropical and Travel Medicine, Hon-
lulu, HI, USA
Food-borne toxins are an important cause of morbidity
n the unwary traveler. In rare situations, deaths may occur.
ducation is the key to prevention and a careful history is
sually the key to diagnosis.
Ingestion of contaminated ﬁsh and shellﬁsh is one of the
ommonest causes of poisoning and the risk from marine
oxins appears to be increasing as a result of multiple fac-
ors such as global warming, coral reef damage and spread
f toxic algal blooms. Important examples include ciguatera
oisoning from ingestion of large carnivorous coral reef ﬁsh,
uffer ﬁsh poisoning and various shellﬁsh poisonings such as
aralytic shellﬁsh poisoning. Scombroid poisoning occurs in
pen ocean ﬁsh such as tuna and mahi mahi that contain his-
idine in the ﬂesh. Inadequate chilling after capture results
n conversion of histidine to histamine and symptoms that
esemble an acute allergic reaction.
In most cases the presence of toxin does not affect the
ppearance, smell or taste of seafood and it is not destroyed
y cooking, smoking, freezing or drying. Onset of illness typ-
cally occurs soon after ingestion of contaminated food and
roduces gastrointestinal symptoms such as diarrhea, nau-
ea, vomiting and abdominal pain often followed by a variety
f neurological and cardio respiratory symptoms. Paradoxi-
al dysesthesiae such as temperature reversal (hot objects
eel cold and cold objects feel hot) are very characteristic
f ciguatera and neurotoxic shellﬁsh poisoning.
Treatment is usually symptomatic and supportive. In the
ase of scombroid poisoning antihistamines provide speciﬁc
reatment and in the case of ciguatera poisoning intravenous
annitol may reduce the severity and duration of some of
he neurological features. Diagnosis is usually based on a
areful history. Test kits that detect ciguatoxin in contami-
ated ﬁsh are commercially available.
Ackee poisoning and cassava poisoning are examples of
ood poisoning from non-marine sources. Ackee poisoning
ccurs after eating unripe ackee fruit and results in vomit-
ng and life threatening hypoglycemia. Acute and chronic
yanide poisoning may occur after ingesting cassava root
roducts containing cyanogenic glycosides. Acute poison-
ng causes diarrhea, vomiting, mental confusion and death.
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Chronic intoxication causes abnormal thyroid function and
various neurological disorders.
doi:10.1016/j.ijid.2010.02.1513
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Epidemiology of Chronic Viral Hepatitis in Latin America
D. Diament
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil
Chronic viral hepatitis caused by Hepatitis B or C viruses
are major health problems in this beginning of the 21st
century. Estimated prevalence in the world population in
different regions range between less than 1% to more than
3% for HCV and between less than 2% to more than 8% for
HBV, affecting more than 400 million people in the world. In
Latin America, prevalence estimates are ﬂawed. For HCV it
varies from less than 1% to 2%, and for HBV from less than
1% to more than 8%. Numbers can be as high as 15% in the
Amazon region.
In Latin America, some surveys report HBV prevalence
as high as 21.4% in Dominican Republic and 7.9% in Brazil,
followed by 3.2% in Venezuela and 2.1% in Argentina. Low
prevalence was found in Mexico (1.4%) and Chile (0.6%). For
HCV, rough estimates project more than 10 million infected
people. Many surveys were conducted by blood banks, but
results are biased by sampling problems.
In Brazil, HCV prevalence studies estimates had found a
wide range, varying from 0.4% to 5.9%. A population based
study in 2007 found a HCV antibodies prevalence of 0.28%
to 2.61% and a HCV-RNA from 0.02% to 0.9% in different
regions of the country. From 1994 to 2005, the Ministry of
Health database has registered 52,440 HCV cases. Recently,
a national survey was conducted by the Ministry of Health,
but results are not published yet.
In São Paulo state, there were 30,299 HCV cases regis-
tered from 2002 to 2008 and 14,810 HBV cases in the same
period. In the city of São Paulo it is estimated a mean
prevalence of 1.42% (95% conﬁdence interval 0.7 — 2.12%).
Diagnosis can be done with blood tests, but availability is a
concern in poor countries.
Treatment is expensive and fairly effective, implying in
high morbidity, mortality and costs. Chronic hepatitis is a
great challenge for the health systems in Latin America.
doi:10.1016/j.ijid.2010.02.1514
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Update on Hepatits B Therapy
E. Savio
Universidad de la Repùblica, Montevideo, Uruguay
Tha main goal for the treatment of chronic hepatitis
B (CHB) is to prevent advanced hepatic disease: cirro-
sis,hepatic failure and hepatocellular carcinoma (HCC).
The ﬁrst aim of treatment is to achieve sustained suppre-
sion of HBV replication as well as the remission of liver
disease.The sustained supression of virological replication
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aries widely,depending on the population on treatment,
herapeutic agent s, treatment duration and less clearly
rom genotype. Since 1992,eigth therapeutic agents have
een approved worlwide (INF alfa, lamivudine, adefovir,
ntecavir, PegINF alfa-2a thymosin alfa1, ,telvibudine and
enofovir) but only some of them are used in different coun-
ries according to national regulation.. When and how to
reat an CHB depends on the HBV DNA levels, ALT and status
f HBeAg. For HBeAg(+) patients,the endpoint of treatment
s HBeAg seroconvertion. Therapy is considered in GHB with
BV DNA leves of 20.000 IU/ml or higer (HBeAg positive
atient) or 2.000 IU/ml (HBeAg negative), although lower
BV DNA levels migth be selected when evidences of pro-
resive disease are identiﬁed. ALT normalization and HBV
NA suppression are the measures of reponse to therapy.
ral nucleoside analogs (NA) is a signiﬁcant contribution for
reatment in the last years,but a major concern with this
gents is the selection of antiviral resistant mutations. This
ay be identiﬁed prior to virological breakthrough or at the
ame time. Peginterferon alfa-2a, entecavir and tenofovir
re currently included in the ﬁrst-line treatment choice on
he basis of their potency as well as the low rate of antiviral
rug resistance. The strategy of drugs combination in CHB
reatment for achieving a sustained virological response and
ome end points has beeen explored and the level of HBV
NA suppression. This combination theraphy is encouraging
n some clinical trials.
oi:10.1016/j.ijid.2010.02.1515
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epatitis C Treatment Today and the Future
. Sarmento e Castro
Hospital Joaquim Urbano, Porto, Portugal
Therapy of chronic HCV infection is based on the use
f the combination of pegylated interferon and ribavirin.
ustained virological response (SVR), a negative HCV RNA
4 weeks following discontinuation of therapy, is the most
mportant surrogate parameter to achieve. Actually, SVR is
btained in about 50% of patients with genotypes 1/4 and in
0% of the patients with genotypes 2/3.
Patients infected with genotypes 1 or 4 must be treated
or 48 weeks. But, if the patient achieves a rapid virological
esponse (RVR), deﬁned as a negative HCV RNA at week 4, we
an consider a shortening of treatment. In patients with a
low response to treatment (HCV RNA only negative between
eeks 12 and 24) the length of therapy must be extended
o 72 weeks. For patients infected with genotypes 2 or 3
reatment should be planned for 24 weeks.
New drugs are needed for non-responders and for those
ho are not good candidates to treatment.
Several new oral agents, more potent, less toxic and
llowing for shorter duration of treatment are being devel-
ped. These new drugs are designed to inhibit several viral
nzymes. Results of recent clinical trials using inhibitors of
S3/4A protease or inhibitors of NS5B polymerase in com-
ination with peginterferon/ribavirin are promising. These
tudies demonstrated that adding telaprevir or boceprevir
the protease inhibitors in the most advanced phases of eval-
ation) to peginterferon/ribavirin improved the rates of SVR
